BioTherapeutics is committed to developing therapies with the aim of saving and sustaining lives. Our pledge is to provide the most effective, safest, and highest quality products and programs that advance patient care globally and enable the achievement of outcomes through innovation, science, and technology.
As a global healthcare company, BioTherapeutics is focused on saving and sustaining the lives of people with rare conditions. We are committed to providing therapies for patients across a broad range of treatment needs such as primary immunodeficiencies (PID) and secondary immunodeficiencies (SID), Immune Thrombocytopenic Purpura, severe congential Protein C deficiency and treatment of hypovolemia.
Read More [+]
Treatment and Diagnosis Awareness Activities in United States, Brazil and Germany
Deerfield, IL/Sao Paulo, Brazil, April 29, 2009
Today, the Jeffrey Modell Foundation (JMF) together with Baxter International Inc. celebrated the opening of the Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies at the Federal University of Sao Paulo, located in Sao Paulo, Brazil. The announcement coincides with the 5th World Day of Immunology (WDI), a day acknowledging how the immune system works to better help people avoid illness and infections. WDI was established through the European Federation of Immunological Societies (EFIS) to strengthen the public awareness of immunology as a basis for individual health and well-being. Baxter WDI awareness activities span from Brazil to the United States and Germany.
Read More [+]
A comprehensive portfolio of Ig products for all treatment settings - hospital, outpatient, clinic, and home.